EMA Application withdrawn: Omontys (peginesatide) — Takeda Global Research and Development Centre (Europe)

View source ↗

Summary

EMA withdrew the application for Omontys (peginesatide) from Takeda, related to anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia

Drugs mentioned

• OMontys (peginesatide)

Snippet

Status: Application withdrawn. Therapeutic area: Anemia. MAH: Takeda Global Research and Development Centre (Europe). Decision date: 28/06/2013. Conditional approval